In this regard, the IFN-DC loaded with antigens from BC patient-derived organoids treated with hypochlorous acid proved to be an optimal antigenic formulation for the development of a personalized breast cancer vaccine, effectively addressing the issue of tumor heterogeneity. Here, IFNA1 is linked to neoplasm.